Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia

• Verfasst von: Amadori, Sergio [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Titel: Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia
• Titelzusatz: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)
• Verf.angabe: Sergio Amadori, Stefan Suciu, Roberto Stasi, Helmut R. Salih, Dominik Selleslag, Petra Muus, Paolo De Fabritiis, Adriano Venditti, Anthony D. Ho, Michael Lübbert, Xavier Thomas, Roberto Latagliata, Constantijn J.M. Halkes, Franca Falzetti, Domenico Magro, José E. Guimaraes, Zwi Berneman, Giorgina Specchia, Matthias Karrasch, Paola Fazi, Marco Vignetti, Roel Willemze, Theo de Witte, and Jean-Pierre Marie
• E-Jahr: 2013
• Jahr: October 14, 2013
• Umfang: 7 S.
• Teil: volume:31
• Teil: year:2013
• Teil: number:35
• Teil: pages:4424-4430
• Teil: extent:7
• Fussnoten: Gesehen am 12.05.2021
• Titel Quelle: Enthalten in: Journal of clinical oncology
• Ort Quelle: Alexandria, Va. : American Society of Clinical Oncology, 1983
• Jahr Quelle: 2013
• Band/Heft Quelle: 31(2013), 35, Seite 4424-4430
• ISSN Quelle: 1527-7755
• DOI: doi:10.1200/JCO.2013.49.0771
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1757759972

Abstract

Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients and Methods Patients (n = 472) age 61 to 75 years were randomly assigned to induction chemotherapy with mitoxantrone, cytarabine, and etoposide preceded, or not, by a course of GO (6 mg/m2 on days 1 and 15). In remission, patients received two consolidation courses with or without GO (3 mg/m2 on day 0). The primary end point was overall survival (OS). Results The overall response rate was comparable between the two arms (GO, 45%; no GO, 49%), but induction and 60-day mortality rates were higher in the GO arm (17% v 12% and 22% v 18%, respectively). With median follow-up of 5.2 years, median OS was 7.1 months in the GO arm and 10 months in the no-GO arm (hazard ratio, 1.20; 95% CI, 0.99 to 1.45; P = .07). Other survival end points were similar in both arms. Grade 3 to 4 hematologic and liver toxicities were greater in the GO arm. Treatment with GO provided no benefit in any prognostic subgroup, with the possible exception of patients age < 70 years with secondary AML, but outcomes were significantly worse in the oldest age subgroup because of a higher risk of early mortality. Conclusion As used in this trial, the sequential combination of GO and standard chemotherapy provides no benefit for older patients with AML and is too toxic for those age ≥ 70 years.